

Application No.: 09/840,008

Attorney Docket No.: SALK2270-4

Filing Date: April 20, 2001

(088802-5211)

Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004

Page 2 of 10

**Listing of Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously presented) An expression system comprising:  
at least one SXR response element operably linked to at least one gene, and  
a nuclear receptor which is a member of the steroid/thyroid hormone superfamily and  
which responds to xenobiotic compounds and binds to said at least one SXR response element as  
a heterodimer with retinoid X receptor (RXR) to activate transcription of said at least one gene;  
wherein said at least one SXR response element comprises a direct or inverted repeat  
response element comprising at least two half sites -RGBNNM- separated by a spacer of 0 up to  
15 nucleotides

wherein:

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are  
identical with the nucleotides at corresponding positions of the sequence AGTTCA.

2. (Original) The expression system of claim 1, wherein said nuclear receptor is a  
steroid xenobiotic receptor.

3. (Withdrawn) The expression system of claim 1, wherein said nuclear receptor is a  
pregnane X receptor.

4. (Previously presented) The expression system of claim 1, wherein said gene  
encodes a cytokine, a hormone, a blood component, therapeutic gene, or a toxic protein.

Application No.: 09/840,008  
Filing Date: April 20, 2001  
Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 3 of 10

Attorney Docket No.: SALK2270-4  
(088802-5211)

5. (Previously presented) The expression system of claim 1, wherein said xenobiotic compound is digitoxin, indomethacin, pregnelone-16-carbonitrile (PCN), tamoxifen, ralozifene, vitamin K, nifedipine, a barbituate or a steroid.

6. (Previously presented) An expression system comprising:  
at least one SXR response element operably linked to at least one gene, and  
an expression vector comprising nucleic acid encoding a receptor which is a member of the steroid/thyroid hormone superfamily and which responds to xenobiotic compounds and binds to said at least one SXR response element as a heterodimer with retinoid X receptor (RXR) to activate transcription of said at least one gene;  
wherein said at least one SXR response element comprises a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides

wherein:

R is selected from A or G;  
B is selected from G, C, or T;  
each N is independently selected from A, T, C, or G; and  
M is selected from A or C;  
with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA.

7. (Original) The expression system of claim 6, wherein said nucleic acid encodes a steroid xenobiotic receptor.

8. (Withdrawn) The expression system of claim 6, wherein said nucleic acid encodes a pregnane X receptor.

Application No.: 09/840,008  
Filing Date: April 20, 2001

Attorney Docket No.: SALK2270-4  
(088802-5211)

Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 4 of 10

9. (Original) The expression system of claim 6, wherein said expression vector constitutively expresses said nucleic acid.

10. (Original) The expression system of claim 6, wherein said expression vector inducibly expresses said nucleic acid.

11. (Previously presented) A method for the production of a target protein in a cell, said method comprising administering to a cell at least one xenobiotic compound, wherein said cell contains:

a nucleic acid comprising at least one SXR response element operably linked to at least one gene encoding said target protein, and

a receptor which is a member of the steroid/thyroid hormone superfamily and which responds to xenobiotic compounds and binds to said at least one SXR response element as a heterodimer with retinoid X receptor (RXR) to activate transcription of said at least one gene;

and wherein said at least one SXR response element comprises a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides

wherein:

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA.

12. (Original) The method of claim 11, wherein said receptor is a steroid/xenobiotic receptor.

Application No.: 09/840,008  
Filing Date: April 20, 2001  
Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 5 of 10

Attorney Docket No.: SALK2270-4  
(088802-5211)

13. (Withdrawn) The method of claim 11, wherein said receptor is a pregnane X receptor.

14. (Original) The method of claim 11, wherein said xenobiotic compound is digitoxin, indomethacin, pregnelone-16-carbonitrile (PCN), tamoxifen, raloxifene, vitamin K, nifedipine, a barbituate or a steroid.

15. (Original) The method of claim 11, wherein said receptor is provided by expression from a nucleic acid construct encoding same.

16. (Previously presented) A method for the production of a target protein in a cell, said method comprising administering to a cell at least one xenobiotic compound and a nucleic acid comprising at least one SXR response element operably linked to at least one gene encoding said target protein,

wherein said cell contains a receptor which is a member of the steroid/thyroid hormone superfamily and which responds to xenobiotic compounds and binds to said at least one SXR response element as a heterodimer with retinoid X receptor (RXR) to activate transcription of said at least one gene;

and wherein said at least one SXR response element comprises a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides

wherein:

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA.

Application No.: 09/840,008  
Filing Date: April 20, 2001.

Attorney Docket No.: SALK2270-4  
(088802-5211)

Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 6 of 10

17. (Original) The method of claim 16, wherein said receptor is a steroid xenobiotic receptor.

18. (Withdrawn) The method of claim 16, wherein said receptor is a pregnane X receptor.

19. (Original) The method of claim 16, wherein said xenobiotic compound is digitoxin, indomethacin, pregnelone-16-carbonitrile (PCN), tamoxifen, ralozifene, vitamin K, nifedipine, a barbituate or a steroid.

20. (Original) The method of claim 16, wherein said receptor is provided by expression from a nucleic acid construct encoding same.

21. (Previously presented) A method for the production of a target protein in a cell, said method comprising administering to a cell at least one xenobiotic compound, and a receptor which is a member of the steroid/thyroid hormone superfamily and which responds to xenobiotic compounds and binds to at least one SXR response element as a heterodimer with retinoid X receptor (RXR) to activate transcription of at least one gene operably linked to said at least one SXR response element,

wherein said cell contains a nucleic acid comprising said at least one SXR response element operably linked to at least one gene encoding said target protein;

and wherein said at least one SXR response element comprises a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides

wherein:

R is selected from A or G;

B is selected from G, C, or T;

each N is independently selected from A, T, C, or G; and

M is selected from A or C;

Application No.: 09/840,008  
Filing Date: April 20, 2001  
Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 7 of 10

Attorney Docket No.: SALK2270-4  
(088802-5211)

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA.

22. (Original) The method of claim 21, wherein said receptor is a steroid xenobiotic receptor.

23. (Withdrawn) The method of claim 21, wherein said receptor is a pregnane X receptor.

24. (Previously presented) A method for the production of a target protein in a cell, said method comprising inducing synthesis in said cell of a receptor which is a member of the steroid/thyroid hormone superfamily and which responds to xenobiotic compounds and binds to at least one SXR response element as a heterodimer with retinoid X receptor (RXR) to activate transcription of at least one gene operably linked to said at least one SXR response element, wherein said cell contains:

an expression vector comprising nucleic acid encoding said receptor operatively associated with an inducible promoter,  
a nucleic acid comprising said at least one SXR response element operably linked to at least one gene encoding said target protein, and  
at least one xenobiotic compound;

and wherein said at least one SXR response element comprises a direct or inverted repeat response element comprising at least two half sites RGBNNM separated by a spacer of 0 up to 15 nucleotides

wherein:

R is selected from A or G;  
B is selected from G, C, or T;  
each N is independently selected from A, T, C, or G; and  
M is selected from A or C;

Application No.: 09/840,008  
Filing Date: April 20, 2001

Attorney Docket No.: SALK2270-4  
(088802-5211)

Response to Office Communication (mailed June 25, 2004) faxed July 22, 2004  
Page 8 of 10

with the proviso that at least 4 nucleotides of said -RGBNNM- sequence are identical with the nucleotides at corresponding positions of the sequence AGTTCA.

25. (Original) The method of claim 24, wherein said receptor is a steroid xenobiotic receptor.
26. (Withdrawn) The method of claim 24, wherein said receptor is a pregnane X receptor.